Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
120
resultados
Última actualización
27/12/2025 [07:05:00]
Resultados 75 a 100 de 120
Resumen de: WO2025231155A2
The application provides a method to prevent or reduce the transmission of a coronavirus, such as a SARS- COV-2 variant, or a paramyxovirus from an infected subject to other uninfected subjects, comprising administrating an anti-viral peptide conjugate to the infected subject, the uninfected subject, or both.
Resumen de: WO2025231182A1
The application provides a pharmaceutical composition, which comprises an antiviral peptide conjugate, for the treatment or prevention of a condition or disease associated with a coronaviral infection. The coronavirus includes human coronavirus OC43, human coronavirus HKU1, human coronavirus 229E, human coronavirus NL63, Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS-CoV, SARS-CoV-2, or any variant thereof. The pharmaceutical composition is designed for, inter alia, intranasal administration.
Resumen de: WO2025230087A1
The present invention relates to an attenuated SARS-CoV-2 vaccine strain including nucleocapsid N gene transcriptional repression and a non-structural protein 1 (nsp1) protein mutation, and a use thereof. The attenuated SARS-CoV-2 vaccine strain according to the present invention has excellent safety and efficacy as a vaccine, and thus can be effectively used as an attenuated live vaccine for the prevention of coronavirus disease 2019.
Resumen de: US2025340957A1
An oligonucleotide, having a 5′ terminus and a 3 terminus, wherein said oligonucleotide is detectably labeled and has a nucleotide sequence that consists essentially of one of the nucleotide sequences selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:60 and SEQ ID NO:77.
Resumen de: WO2025230306A1
The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.
Resumen de: WO2025227322A1
Provided are a broad-spectrum anti-COVID-19 vaccine immunogen composition, and the preparation and a use thereof. Specifically, provided is an immunogen composition, comprising an RBD recombinant chimeric antigen, wherein the chimeric antigen comprises S protein RBD domains from two or more COVID-19 subtypes, or functional fragments thereof. The immunogen composition can further comprise a multimerization domain and a T-cell immunogen domain. Further provided are a use of the immunogen composition, a corresponding encoding molecule therefor, a vector, and/or a host cell in preparing an anti-COVID-19 vaccine. The vaccine can induce a broad-spectrum protective effect against a prototype strain and various currently prevalent variants, and can also elicit a potent cross-protective T-cell response, thereby achieving effective and broad-spectrum prevention against COVID-19 and achieving a protective effect against other coronaviruses.
Resumen de: KR20250157984A
본 발명은 SARS-CoV-2 B.1.617.2 RBD에 특이적인 단일도메인 항체 및 이의 용도에 관한 것이다. 본 발명의 SARS-CoV-2 B.1.617.2의 스파이크 단백질의 RBD에 특이적으로 결합하는 중쇄 항체 또는 이의 항원 결합 단편은 B.1.617.2 변이에 특이적으로 결합하는 단일도메인 항체를 포함하는 것으로서, 높은 친화도 및 특이성을 바탕으로 바이러스성 질환 치료제 및 진단용 조성물로서 유용하게 사용될 수 있다.
Resumen de: KR20250157983A
본 발명은 SARS-CoV-2 BA.2 RBD에 특이적인 단일도메인 항체 및 이의 용도에 관한 것이다. 본 발명의 SARS-CoV-2 BA.2의 스파이크 단백질의 RBD에 특이적으로 결합하는 중쇄 항체 또는 이의 항원 결합 단편은 BA.2 변이에 특이적으로 결합하고 이를 중화할 수 있는 단일도메인 항체를 포함하는 것으로서, 높은 친화도 및 특이성을 바탕으로 바이러스성 질환 치료제 및 진단용 조성물로서 유용하게 사용될 수 있다.
Resumen de: KR20250156928A
본 발명은 MERS-CoV RBD에 대한 인간 항체 및 이의 용도에 관한 것이다. 본 발명의 항체 또는 그의 항원 결합 단편은 MERS-CoV RBD에 특이적으로 결합하여 MERS-CoV의 감염을 억제할 수 있으며, 본 발명의 이중항체는 서로 다른 에피토프를 가진 2종의 항체 또는 항원 결합 단편을 포함하고, 단일클론항체 및 두 단일클론항체의 조합보다 더 우수한 중화효능을 가지므로 MERS의 치료제로서 유용하게 사용될 수 있다.
Resumen de: MX2025010057A
The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Resumen de: MX2025010056A
The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, <i>e.g.</i>, to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Resumen de: MX2025012626A
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: AU2024231716A1
The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.
Resumen de: AU2024234602A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Resumen de: CN120860182A
The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.
Resumen de: CN120878272A
The invention provides an infectious disease early-stage dynamics reconstruction method based on an ensemble population model, and belongs to the technical field of infectious disease modeling and risk assessment. Compared with a traditional ensemble population model which only pays attention to a single dimension such as space or age, the method of the invention is incorporated into age grouping, prefecture-level city migration and multiple disease states at the same time, so that the resolution of the model is significantly improved, and the method is more suitable for actual propagation scenes such as COVID-19 cross-age and cross-city propagation characteristics; states such as an asymptomatic infected person and a symptom prosperity period are introduced, the relative infectivity is quantified, and compared with a traditional model, early-stage propagation dynamics is described more accurately; a differential evolution adaptive metropolis algorithm-DREAM algorithm is adopted to replace a traditional Markov chain Monte Carlo method MCMC, through multi-chain parallel search and adaptive parameter adjustment, the parameter convergence speed is increased, and the method is particularly suitable for rapid fitting under the early data sparse condition.
Resumen de: CN120860183A
The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.
Resumen de: CN120860181A
The invention discloses an application of a protein substance in preparation of a composition for inhibiting coronavirus. The coronavirus inhibition comprises the following steps: inhibiting adhesion of the coronavirus on host cells; the invasion of coronavirus to host cells is hindered; the after-cell entry process of coronavirus infection is inhibited. In-vitro verification is carried out on the antiviral effect of the coronavirus GXP2V on various nutritional ingredients (whey protein, milk fat globule membrane, lactoferrin and milk-derived osteopontin), and the result shows that the coronavirus resisting activity of the whey protein, the milk fat globule membrane, the lactoferrin and the milk-derived osteopontin (LPN, short for lactopontin). At present, it is rarely reported that protein substances are used for resisting the coronavirus, the coronavirus GXP2V is a novel coronavirus-like virus, a new thought is developed for resisting the novel coronavirus-like virus, and the application value and prospect are very good.
Resumen de: CN120870582A
The invention discloses a novel coronavirus antibody affinity detection kit, a detection method and application. The kit comprises a magnetic particle reagent, a sample treating fluid, a contrast treating fluid and a detection reagent, the magnetic particle reagent comprises coated magnetic particles, the coated magnetic particles are magnetic particles coated with solid-phase antigens, the solid-phase antigens comprise novel coronavirus recombinant spike protein and nucleocapsid protein, and the sample treating fluid is used for detecting the novel coronavirus recombinant spike protein and the nucleocapsid protein. The sample treatment liquid and the control treatment liquid comprise same sample dilution components, the sample treatment liquid further comprises free antigens, the free antigens comprise novel coronavirus recombinant spike proteins and nucleocapsid proteins, and the control treatment liquid does not comprise the novel coronavirus recombinant spike proteins and nucleocapsid proteins. The detection reagent comprises an IgG antibody marked by a chemiluminescent marker. The kit can conveniently and efficiently detect the affinity of the novel coronavirus antibody, and the detection result is accurate and reliable.
Resumen de: WO2025225632A1
The purpose of the present invention is to provide an antiviral agent effective against COVID-19. The purpose can be achieved by (1) a polypeptide that contains an amino acid sequence selected from the group consisting of the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, and the amino acid sequence represented by SEQ ID NO: 8, or (2) a polypeptide that has antiviral activity against coronavirus, contains an amino acid sequence in which one amino acid is substituted in the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, or the amino acid sequence represented by SEQ ID NO: 8, said polypeptide having an O-glycoside-linked sugar chain.
Resumen de: US2025333806A1
Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the specific and differential detection of SARS-CoV-2, including SARS-CoV-2 variants, or other coronaviruses from samples including veterinary samples, clinical samples, food samples, forensic sample, an environmental sample (e.g., soil, dirt, garbage, sewage, air, or water), including food processing and manufacturing surfaces, or a biological sample.
Resumen de: US2025333809A1
Disclosed are oligonucleotide primers that hybridize specifically with any base sequence designed from the base sequences of the N gene, RNA-dependent RNA polymerase gene, M gene, and S gene of SARS-COV-2, a nucleic acid amplification method using said primers, a test method for SARS-COV-2 infection by detection of nucleic acid amplification, and a COVID-19 test kit.
Resumen de: US2025333485A1
This disclosure provides anti-SARS-COV-2 antibodies or antigen-binding fragments thereof targeting the N-terminal domain (NTD) of the spike(S) protein. The disclosed anti-SARS-COV-2 antibodies or antigen-binding fragments thereof have broadly neutralizing activities against several SARS-COV-2 variants of concern. The disclosed anti-SARS-COV-2 antibodies represent a therapeutic strategy in protecting from SARS-COV-2 infections.
Resumen de: US2025332177A1
A methylene blue COVID-19 composition for treating short-term and long-term COVID-19 symptoms. The methylene blue COVID-19 composition consists of methylene blue and aspirin. The amount of methylene blue in the overall composition is in the range of about 50 mg to 300 mg, while the amount of aspirin in the overall composition is in the range of about 80 mg to 350 mg. The methylene blue COVID-19 composition is formed as a powder that is dissolvable in water or another beverage for patient consumption. The overall composition is used as a treatment for up to about 6 months after testing positive for a COVID-19 infection, in order to effectively treat various symptoms of COVID-19 infections. The methylene blue COVID-19 composition is dissolved in liquid to be a standalone methylene blue COVID-19 solution. In one embodiment, the methylene blue COVID-19 composition is in a pill form.
Nº publicación: US2025333452A1 30/10/2025
Solicitante:
FLAGSHIP PIONEERING INNOVATIONS VII LLC [US]
Flagship Pioneering Innovations VII, LLC
Resumen de: US2025333452A1
Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection; vaccination against SARS-CoV-2.
BOPI
Sede Electrónica
